Suggested remit: To appraise the clinical and cost effectiveness of faricimab within its marketing authorisation for treating macular oedema secondary to retinal vein occlusion.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process Cost Comparison Standard
ID number 6197

Provisional Schedule

Expected publication 14 August 2024

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd


Companies sponsors Roche (faricimab)
Others Department of Health and Social Care
  NHS England
Patient carer groups Macular Society
Professional groups Royal College of Physicians
Associated public health groups None
Comparator companies AbbVie (dexamethasone intravitreal implant) (confidentiality agreement signed, participating)
  Bayer (aflibercept) (confidentiality agreement signed, participating)
  Biogen Biosimilars (ranibizumab) (confidentiality agreement not signed, not participating)
  Genus Pharmaceuticals (ranibizumab) (confidentiality agreement not signed, not participating)
  Novartis (ranibizumab) (confidentiality agreement not signed, not participating)
  Teva UK (ranibizumab) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups None


Key events during the development of the guidance:

Date Update
08 February 2024 Invitation to participate
18 September 2023 - 16 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6197
23 December 2022 In progress. DHSC referral received
22 September 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual